Oncología Traslacional
ONCTRAS
David Geffen School of Medicine at UCLA
Los Ángeles, Estados UnidosPublicaciones en colaboración con investigadores/as de David Geffen School of Medicine at UCLA (4)
2024
-
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
Gynecologic Oncology, Vol. 184, pp. 168-177
-
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Annals of Oncology, Vol. 35, Núm. 11, pp. 981-992
2023
-
Association of Multiple High-Risk Factors on Observed Outcomes in Real-World Patients With Advanced Ovarian Cancer Treated With First-Line Therapy
JCO clinical cancer informatics, Vol. 7, pp. e2200189
-
Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance
Oncology and Therapy, Vol. 11, Núm. 2, pp. 245-261